Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.

News and commentary from the endocrinology world